Takeda Pharmaceutical (TAK) Liabilities from Discontinued Operations (2018 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Liabilities from Discontinued Operations of 14862875.08 for Q2 2026, up 184.95% quarter-over-quarter from 5216017.89 in Q1 2026.
Takeda Pharmaceutical (TAK) Liabilities from Discontinued Operations (2018 - 2026) Analysis & Trends
Takeda Pharmaceutical's Liabilities from Discontinued Operations history runs 8 years deep, the most recent figure standing at 14862875.08 for Q2 2026.
- In Q2 2026, Liabilities from Discontinued Operations changed N/A year-over-year to 14862875.08; the TTM figure through Jun 2026 stood at 14862875.08 (changed N/A YoY), while the FY2026 annual figure was 5434125.06, changed N/A from the prior year.
- Liabilities from Discontinued Operations for Q2 2026 stood at 14862875.08, up from 5216017.89 in the prior quarter.
- The five-year high for Liabilities from Discontinued Operations was 14862875.08 in Q2 2026, with the low at 1088635.11 in Q1 2023.
- The 5-year median for Liabilities from Discontinued Operations is 5705544.64 (2022), against an average of 7104189.78.
- Peak annual rise in Liabilities from Discontinued Operations reached 773.98% in 2024, while the deepest fall reached 773.98% in 2024.
- Takeda Pharmaceutical's Liabilities from Discontinued Operations stood at 8302867.7 in 2022, then slumped by 86.89% to 1088635.11 in 2023, then soared by 745.6% to 9205448.04 in 2024, then slumped by 44.66% to 5094354.11 in 2025, then jumped by 191.75% to 14862875.08 in 2026.
- Business Quant data shows TAK's Liabilities from Discontinued Operations at 14862875.08 in Q2 2026, 5216017.89 in Q1 2026, and 5094354.11 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.86 Mn |
| Jun 30, 2026 | 14.86 Mn |
| Mar 31, 2026 | 5.22 Mn |
| Mar 31, 2026 | 5.22 Mn |
| Dec 31, 2025 | 5.09 Mn |
| Dec 31, 2025 | 5.09 Mn |
| Sep 30, 2025 | 4.95 Mn |
| Sep 30, 2025 | 4.95 Mn |
| Jun 30, 2024 | 9.21 Mn |
| Jun 30, 2024 | 9.21 Mn |
| Mar 31, 2024 | 9.51 Mn |
| Mar 31, 2024 | 9.51 Mn |
| Mar 31, 2023 | 1.09 Mn |
| Mar 31, 2023 | 1.09 Mn |
| Dec 31, 2022 | 8.30 Mn |
| Dec 31, 2022 | 8.30 Mn |
| Sep 30, 2022 | 5.71 Mn |
| Sep 30, 2022 | 5.71 Mn |
| Dec 31, 2020 | 222.85 Mn |
| Dec 31, 2020 | 222.85 Mn |